---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-031273"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:49:20.294494+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vir Bio Q1 net loss $125.7M; cash $809.3M; positive CHD data; VIR-5500 collaboration closed

## Summary
- Net loss of $125.7M ($0.85 per share) vs $121M ($0.88) in Q1 2025.
- Cash, cash equivalents, and investments $809.3M at March 31, 2026; plus $315M Astellas upfront and equity in Q2.
- Phase 2 SOLSTICE: 77% (24/31) HDV RNA undetectable at Week 72, rising to 88% (21/24) at Week 96.
- Phase 3 ECLIPSE 1 topline data expected Q4 2026; ECLIPSE 2/3 in Q1 2027.
- Completed $172.5M public offering; closed Astellas collaboration for VIR-5500; first patient dosed in Phase 1 expansion.

## SEC filing metadata
- accession: 0001628280-26-031273
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828026031273/0001628280-26-031273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828026031273/vir-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-031273
- JSON: https://secwatch.observer/filing/0001628280-26-031273.json
- Plain text: https://secwatch.observer/filing/0001628280-26-031273.txt

## Source-grounded claims
- claim_id: 7db90ffea4bff070550bbd7560aa9b6bedf301e1
  claim: Vir Biotechnology, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss for the first quarter of 2026 was $125.7 million, or $0.85 per share, basic and diluted, EPS $0.85 per share, basic and diluted.
  evidence_excerpt: On May 6, 2026, Vir Biotechnology, Inc. (the Company) issued a press release announcing its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000162828026031273/0001628280-26-031273-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.